Galena Fires CEO Ahn, Offers No Parting Gifts

Galena Biopharma ( GALE) dribbled out more details about the firing of CEO Mark Ahn in a regulatory filing Friday night. 

The parting of the way between Ahn and the scandal-ridden biotech company was not amicable. 

Galena's latest 8-K:


In accordance with the terms of his employment agreement dated as of March 31, 2011, as amended by the first amendment thereto dated as of May 8, 2014, no severance or other compensation is payable to Dr. Ahn. There was no additional or accelerated vesting of Dr. Ahn's stock options, and the options that were vested as of his resignation will remain outstanding and exercisable in accordance with their respective terms. [Emphasis mine.]

CEOs who leave companies on good terms get cushy severance packages. Ahn did not. 

From Galena's last proxy statement, here's how Galena would have treated Ahn's departure "without cause."

The employment agreement provides that if we terminate Dr. Ahn's employment without "cause" (as defined in the employment agreement) during the Term or if he terminates his employment for "good reason" (as defined in the employment agreement) then he is entitled to: (i) continue receiving his then current annualized base salary and medical benefits for a period of twelve months following such termination (the "Severance Period") and (ii) continued vesting for his option for the duration of the Severance Period.

Ahn was fired by Galena's board for cause. 

On Saturday, Ahn sent the following email to his friends and business contacts:

Dear Friends:

Apologies for the mass email, but I wanted to let you know I left Galena Biopharma after serving seven years on the board and/or CEO. I'm looking forward to the new adventure and truly appreciate your thoughtful messages.

Below and attached are my same permanent coordinates in Portland. Take care, have a wonderful end of Summer, and hope to see you soon.

Warmest regards,
Mark

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

How to Dig Deep for Value in These Exuberant Markets

How to Dig Deep for Value in These Exuberant Markets

Value Investors Have to Go Deeper

Value Investors Have to Go Deeper

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments

How to Expertly Trade Monday's Most Active Stocks -- AMD, Newell Brands, Hasbro and More